Advanced in Prothrombin Deficiency

Dr. Usha S. Perepu

University Of Texas Health Science Center At San Antonio
San Antonio, TX
Advanced
in Prothrombin Deficiency
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Usha Perepu is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Perepu and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Von Willebrand Disease (VWD), Myeloproliferative Neoplasms (MPN), Heyde Syndrome, Bone Marrow Aspiration, and Splenectomy. Dr. Perepu is currently accepting new patients.

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IA
Hospital Affiliations
University Health System
Languages Spoken
English
Hindi
Telugu
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Sanford Health
  •  Wellmark
  •  Medica
  •  Humana

Locations

UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7979 Wurzbach Rd, San Antonio, TX 78229
210-450-9000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Enrollment Status: Completed
Publish Date: August 04, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 3 Less Clinical Trials

13 Total Publications

Extracellular histones: a unifying mechanism driving platelet-dependent extracellular vesicle release and thrombus formation in COVID-19.
Extracellular histones: a unifying mechanism driving platelet-dependent extracellular vesicle release and thrombus formation in COVID-19.
Journal: Journal of thrombosis and haemostasis : JTH
Published: November 21, 2023
Similar Doctors
Expertise in
0
conditions
Dr. Albert J. Wood
Hematology Oncology | Hematology | Oncology
Expertise in
0
conditions
Dr. Albert J. Wood
Hematology Oncology | Hematology | Oncology
New Braunfels, TX 
 (28.8 mi)
512-787-1031
Languages Spoken:
English

Albert Wood is a Hematologist Oncology specialist and a Hematologist in New Braunfels, Texas. Dr. Wood and is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Familial Colorectal Cancer, Thrombocytopenia, Lynch Syndrome, and Colorectal Cancer.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile